FORMULATION DEVELOPMENT AND EVALUATION OF pH TRIGGERED IN SITU OPHTHALMIC GEL OF BESIFLOXACIN HYDROCHLORIDE
The aim of the present work was to formulation and evaluation of pH Triggered in-situ Ophthalmic Gel of Besifloxacin Hydrochloride to overcome the drawbacks obtained by conventional eye drop. There are two independent variables were used i.e. Carbopol 934 and HPMC K100. Carbopol 934 were used as gelling agent and HPMC K100 were used as bioadhesive polymer. Besifloxacin Hydrochloride shows activity against a wide range of Gram-positive and negative ocular pathogens: examples are Corynebacterium pseudodiphtheriticum, Moraxella lacunata, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae and Streptococcus salivarius. The in situ gelling system involves sol-to-gel transition in the cul-de-sac upon instillation to avoid pre corneal elimination. The formulations were prepared by 32 factorial design. The prepared formulations were evaluated for clarity, pH, viscosity, Bioadhesive strength of gel, gel strength gel, Drug Content, In-vitro Drug Release Study, Antibacterial Activity, Isotonicity Evaluation, HET-CAM Test and stability studies. The drug content was in the range of 97-99.57 %. Formulation F5 selected as optimized on the basis of evaluation. It shows highest drug release upto 8hrs. It shows good antibiotic activity against Staphylococcus aureus. The optimized formulation was isotonic with blood cells. It passes sterility test. The optimized formulation passes the ocular irritancy test i.e. HET-CAM Test. The formulation kept for the stability study for 3 months. Short term stability study indicates that room temperature 400±20 was appropriate storage condition for formulations.
Keywords: pH Triggered, bioadhesive polymer, Carbopol 934, HPMC K100, HET-CAM Test, Antibacterial Activity.
2. Geeta MP, Madhubhai MP. Recent Advances and Challenges in Ocular Drug Delivery Systems, Pharma Times, 2007; 39(1):21-25.
3. Malik APH, Satyananda S. pH-induced in situ gelling system of an anti-infective drug for sustained ocular delivery, J appl pharma sci, 4(1):101-104.
4. Tinu T S, Litha T, Kumar AB. Polymers Used in Ophthalmic in Situ Gelling System, Int J Pharm Sci Rev Res, 2013; 20(1):176-183.
5. Gambhire S, Bhalerao K, Singh S. In situ Hydrogel: Different Approaches to Ocular Drug Delivery, Int J Pharm Sci, 2013; 5(2):27-36.
6. Chand S, Sharma A. pH Sensitive in Situ Ocular Gel: A Review, J pharm sci bio-sci res, 2016; 6(5):411-417.
7. Shinkar DM, Dhake AS, Setty CM. Drug Delivery From the Oral Cavity: A Focus on Mucoadhesive Buccal Drug Delivery Systems, PDA J Pharm Sci and Tech, 2012; 66:466-500.
8. Deshmukh PK, Fursule RA. Study of a novel environmental responsive ophthalmic drug delivery system, Int J Pharm Biol Sci, 2010; 1(2):1-13.
9. Askarkara SS, Ganorkara AV, Guptaa KR. Design of Experiment Based Validated Stability Indicating Method for Determination of Besifloxacin Hydrochloride in Bulk Drug and Formulation, Biomed J Sci & Tech Res, 2018; 4(4):1-9.
10. Ikeagwu IJ, Amadi ES, Iroha IR. Antibiotic sensitivity pattern of Staphylococcus aureus in Abakaliki, Nigeria, Pak J Med Sci, 2008; 24(2):231-235.
11. Charde YM, Sharma PH, Choudhary NG, Avari JG. Development and Evaluation of herbal formulation for the treatment of Acne, Int J Pharm Sci Res, 2014; 6(6):2250-2260.
12. Gondkar SB, Kute PR, Saudagar RB. Formulation, Development and Evaluation Of Ofloxacin In-Situ Ophthalmic Gel, World J Pharm Pharma Sci, 2015; 4(11): 800-822.
13. Verma L, Sakir M, Singh N, Mehra R, Mehan S. Development of phase change solutions for ophthalmic drug delivery based on ion activated and pH induced polymers, Int J Pharm Prof Res, 2010; 1(2):127-134
14. Indian Pharmacopoeia, Government of India, Ministry of Health and Family Welfare, Published by the Indian Pharmacopoeia Commission, Ghaziabad, 2014:59.
15. United States Pharmacopoeial Convention. The United States Pharmacopoeia, 38th Rev. and The National Formulary, 33rd ed. Twinbrook Parkway, Rockville, MD; 2015:125.
16. Cristina L, Chiva C, Herda R, Corrisitex. BCOP and HET-CAM as alternative methods to animal experimentation, Braz J Pharm Sci, 2009:44.
17. Saudagar RB, Ghodke RD. Formulation Development and Evaluation of Betamethasone Sodium Phosphate In-Situ Ophthalmic Gel, Eur j biomed pharm sci, 2017; 4(10):478-491.
18. Lucas TI, Bishara RH, Seevers RH. A Stability Program for the Distribution of Drug Products: Pharmaceutical Technology, 2004: p.69-73.
19. Cartensen JT, Rhodes CT. Drug Stability: Principles and Practices. Third edition: Informa Healthcare: p.582-590.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).